These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 3909316)
1. Aztreonam: antibacterial activity, beta-lactamase stability, and interpretive standards and quality control guidelines for disk-diffusion susceptibility tests. Barry AL; Thornsberry C; Jones RN; Gavan TL Rev Infect Dis; 1985; 7 Suppl 4():S594-604. PubMed ID: 3909316 [TBL] [Abstract][Full Text] [Related]
2. The anti-microbial activity, beta-lactamase stability, and disk diffusion susceptibility testing of carumonam (RO 17-2301, AMA-1080), a new monobactam. Jones RN; Barry AL; Thornsberry C; Fuchs PC; Packer RR Am J Clin Pathol; 1986 Nov; 86(5):608-18. PubMed ID: 3096130 [TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro antibacterial activity of aztreonam against clinical isolates of gram-negative bacteria. Shibl AM; Ishag AH; Durgham SM Chemotherapy; 1989; 35 Suppl 1():72-6. PubMed ID: 2659292 [TBL] [Abstract][Full Text] [Related]
4. Use of cefotaxime or ceftazidime susceptibility tests for predicting susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa. Heym B; Lacroix O; Péan Y; Gertner J; Nicolas MH; Jarlier V J Antimicrob Chemother; 1994 Apr; 33(4):729-35. PubMed ID: 8056691 [TBL] [Abstract][Full Text] [Related]
5. In vitro activity against aerobic and anaerobic gram-positive and gram-negative bacteria and beta-lactamase stability of RS-533, a novel carbapenem. Neu HC; Chin NX; Saha G; Labthavikul P Antimicrob Agents Chemother; 1986 Dec; 30(6):828-34. PubMed ID: 3545068 [TBL] [Abstract][Full Text] [Related]
6. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830). Jones RN; Barry AL Diagn Microbiol Infect Dis; 1989; 12(6):495-510. PubMed ID: 2560422 [TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro antimicrobial activity of carumonam, a new monocyclic beta-lactam. Smith BR; LeFrock JL; McCloskey RV; Donato JB; Weber SJ; Joseph WS Antimicrob Agents Chemother; 1986 Feb; 29(2):346-9. PubMed ID: 3087280 [TBL] [Abstract][Full Text] [Related]
8. In vitro activity of a new cephalosporin ME-1206 compared with other agents. Chin NX; Zhang YX; Neu HC Diagn Microbiol Infect Dis; 1991; 14(5):417-24. PubMed ID: 1797456 [TBL] [Abstract][Full Text] [Related]
9. Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia using the Etest method. The Colombian Antimicrobial Resistance Study Group. Jones RN; Salazar JC; Pfaller MA; Doern GV Diagn Microbiol Infect Dis; 1997 Dec; 29(4):265-72. PubMed ID: 9458984 [TBL] [Abstract][Full Text] [Related]
10. In vitro activity of piperacillin, ticarcillin, mezlocillin, ticarcillin-clavulanic acid, aztreonam, ceftazidime, azlocillin, cefoperazone, and thienamycin against Pseudomonas aeruginosa. Greenberg RN; Bollinger MR; Alivisatos MR Clin Ther; 1986; 8(6):655-7. PubMed ID: 3098426 [TBL] [Abstract][Full Text] [Related]
11. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests. Jones RN; Barry AL; Thornsberry C; Gerlach EH; Fuchs PC; Gavan TL; Sommers HM J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985 [TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activity and beta-lactamase stability of CGP 31523A, a new aminothiazolyl cephalosporin. Chin NX; Neu HC Chemioterapia; 1986 Apr; 5(2):92-100. PubMed ID: 3518967 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin. Fuchs PC; Jones RN; Barry AL; Thornsberry C Antimicrob Agents Chemother; 1985 May; 27(5):679-82. PubMed ID: 3893316 [TBL] [Abstract][Full Text] [Related]
14. Comparative activity of newer antibiotics against gram-negative bacilli. Knapp CC; Washington JA Cleve Clin J Med; 1989; 56(2):161-6. PubMed ID: 2731335 [TBL] [Abstract][Full Text] [Related]
15. Susceptibility testing of carumonam: interpretive criteria for 30-microgram disk tests and quality control guidelines for disk diffusion and broth microdilution methods. Jones RN; Barry AL J Clin Microbiol; 1987 Nov; 25(11):2243-6. PubMed ID: 3693552 [TBL] [Abstract][Full Text] [Related]
16. Gram-negative bacilli resistant to third-generation cephalosporins: beta-lactamase characterization and susceptibility to Sch 34343. Medeiros AA; Hare R; Papa E; Adam C; Miller GH J Antimicrob Chemother; 1985 Jun; 15 Suppl C():119-32. PubMed ID: 3875602 [TBL] [Abstract][Full Text] [Related]
17. Criteria for disk susceptibility tests and quality control guidelines for the cefoperazone-sulbactam combination. Barry AL; Jones RN J Clin Microbiol; 1988 Jan; 26(1):13-7. PubMed ID: 3343304 [TBL] [Abstract][Full Text] [Related]
18. The in-vitro activity and beta-lactamase stability of carumonam. Neu HC; Chin NX; Labthavikul P J Antimicrob Chemother; 1986 Jul; 18(1):35-44. PubMed ID: 3531143 [TBL] [Abstract][Full Text] [Related]
19. [Comparative in vitro activity of 2 monobactams (RO 172301 (AMA 1080)and aztreonam), ceftazidime and cefotaxime on Gram-negative bacilli]. Thabaut A; Meyran M; Huerre M Pathol Biol (Paris); 1985 May; 33(5):404-7. PubMed ID: 3929217 [TBL] [Abstract][Full Text] [Related]
20. Ceftriaxone: a summary of in vitro antibacterial qualities including recommendations for susceptibility tests with 30-micrograms disks. Jones RN; Barry AL; Thornsberry C Diagn Microbiol Infect Dis; 1983 Dec; 1(4):295-311. PubMed ID: 6321093 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]